来曲唑在激素受体阳性晚期乳腺癌患者内分泌治疗中的疗效观察

Therapeutic Effect of Letrozole on Endocrine Therapy of Hormone Receptor-positive Advanced Breast Cancer

目的:观察来曲唑在激素受体阳性晚期乳腺癌患者内分泌治疗中的临床疗效。方法:选取我院74例激素受体阳性晚期乳腺癌患者,采用随机数字表法分组,各37例。对照组予以三苯氧胺治疗,观察组予以来曲唑治疗。对比两组临床治疗、不良反应发生率、治疗前后简明健康状况调查量表(SF-36)评分、孕激素受体(PR),雌激素受体(ER),阳性率。结果:观察组客观有效率70.27%(26/37)较对照组45.95%(17/37)高(P<0.05);治疗后观察组疼痛程度、生理职能、精力、一般健康状况评分较对照组高(P<0.05);治疗前后两组PR、ER阳性率对比,差异无统计学意义(P>0.05),治疗后观察组PR阳性率48.65%较治疗前72.97%低,ER阳性率56.76%较治疗前81.08%低(P<0.05);观察组不良反应发生率13.51%(5/37)与对照组18.92%(7/37)对比,差异无统计学意义(P>0.05)。结论:来曲唑用于激素受体阳性晚期乳腺癌内分泌治疗中,疗效显著,可促使PR、ER转阴,提高患者生活质量,具有一定安全性。

Objective: To observe the clinical efficacy of letrozole on endocrine therapy of hormone receptor-positive advanced breast cancer. Methods: Seventy-four patients with hormone receptor-positive advanced breast cancer were enrolled in our hospital. All patients were randomized by digital table method, with 37 cases in each group. The control group was treated with tamoxifen, and the observation group was treated with letrozole. The clinical treatment, adverse reaction rate, concise health status survey scale (SF-36) score, PR and ER positive rate were compared between the two groups. Results: The objective effective rate of the observation group was 70.27%(26/37), which was higher than that of the control group (45.95%(17/37)). After treatment, the pain degree, physiological function, energy and general health status of the observation group were higher than those of the control group.(P<0.05);There was no significant difference in the positive rate of PR and ER between the two groups before and after treatment (P>0.05). After treatment, the positive rate of PR in the observation group was 48.65% lower than that before treatment, and the ER positive rate was 56.76%. 81.08% before treatment was low (P <0.05);the incidence of adverse reactions in the observation group was 13.51%(5/37) compared with 18.92%(7/37) in the control group, and the difference was not statistically significant (P>0.05). Conclusion: Letrozole is effective in the endocrine therapy of hormone receptor-positive advanced breast cancer, which can promote PR and ER to negative, improve the quality of life of patients, and has certain safety.